Medacta Group (MOVE) Fair Value & Analysis
Healthcare · CH · Market cap CHF 2.8B
Fair value as of: Jul 13, 2026
From 26 valuation models · updated 27 days ago
Fair value updated Jul 13, 2026, revised from CHF 93.96 to CHF 79.97 (−14.9%) since Jun 24, 2026. Share price −1.9% over the past month.
A solid business, but screening 40% overvalued on our models.
What matters now
- The model range is unusually wide (CHF 38.00 to CHF 137.51). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 13, 2026.
How to read this chart
60‑month range CHF 76.78 – CHF 174.65 · fair‑value band CHF 38.00 – CHF 137.51 · the CHF 132.60 price screens above the CHF 79.97 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 13, 2026.
Analysis
Medacta Group (MOVE) currently trades at CHF 132.60, while our model-based Fair Value estimate is CHF 79.97, implying the stock looks roughly 39.7% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Medacta Group generated revenue of CHF 684M at a net margin of 14.0%. Revenue grew 12.5% year over year. It earns a return on equity of 22.8%. Net debt stands at CHF 229M. Fundamentals as of Jul 13, 2026
Our scenario range runs from CHF 38.00 (bear case) to CHF 137.51 (bull case); at CHF 132.60, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 25% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -40%, MOVE screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (CHF 114.16) versus Dividend Discount (CHF 11.21). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery.
Full company description
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medacta Group reported revenue of CHF 688M in FY2025 versus CHF 363M in FY2021, a compound +17.3%/yr. Reported net income was CHF 96.1M in FY2025, compounding +16.9%/yr from FY2021.
MOVE screens 40% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Medacta Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medacta Group (MOVE) overvalued or undervalued?
What is the fair value of MOVE?
What is the quality score of MOVE?
What is the revenue of Medacta Group (MOVE)?
What is the net profit margin of MOVE?
Does Medacta Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Medacta Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.